Himavat (Atorvastatin, Ezetimibe)

Himavat is indicated for the management of several lipid disorders in adult patients.

• Hypercholesterolemia (primary or secondary) requiring additional LDL‑C reduction.
• Mixed dyslipidemia with elevated LDL‑C and triglycerides.
• Primary hyperlipidemia not adequately controlled by diet alone.
• Prevention of cardiovascular events in patients at high or moderate risk when combined with lifestyle modification.
• Adjunct therapy for patients with familial hypercholesterolemia who need further LDL‑C lowering.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL‑C. Ezetimibe selectively blocks the NPC1L1 transporter on enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. By addressing both endogenous synthesis and exogenous intake, the fixed‑dose combination provides a broader lipid‑lowering profile than either agent alone.

Like all lipid‑lowering therapies, Himavat may cause adverse reactions, most of which are mild and transient.

Common

• Headache
• Myalgia or muscle cramps
• Abdominal discomfort
• Diarrhea
• Transient elevation of liver enzymes

Serious

• Rhabdomyolysis with severe muscle pain and dark urine
• Acute liver injury with marked transaminase elevation
• Severe allergic reactions such as angioedema or anaphylaxis
• Gallbladder disease (e.g., cholelithiasis) associated with ezetimibe

Before initiating Himavat, clinicians should evaluate patient history and laboratory parameters to minimize risks.

• Assess baseline liver function tests; avoid use in patients with active hepatic disease.
• Review renal function, especially in severe impairment, as dose adjustment may be needed.
• Screen for a history of muscle disorders or concomitant use of strong CYP3A4 inhibitors.
• Use with caution in pregnant or breastfeeding women; safety data are limited.
• Monitor lipid profile periodically to assess efficacy and adjust therapy.
• Counsel patients on the importance of diet, exercise, and adherence.

Himavat can interact with several medicines that affect its metabolism or increase the risk of adverse effects.

Avoid

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors).
• Concurrent use of other cholesterol‑lowering agents such as fibrates or high‑dose niacin, which may raise the risk of muscle toxicity.
• Bile acid sequestrants taken within 2 hours of the dose, as they can reduce ezetimibe absorption.

Use with caution

• Anticoagulants (e.g., warfarin) – may require closer INR monitoring.
• Cyclosporine – can increase statin concentrations and muscle‑related side effects.
• Grapefruit juice – may modestly raise atorvastatin levels.
• Antidiabetic drugs – statins may affect glucose control, requiring periodic monitoring.